4-(bromomethyl)-5-(tert-butyl)-1,3-dioxol-2-one | 86005-12-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 4-(bromomethyl)-5-(tert-butyl)-1,3-dioxol-2-one
• 英文别名: 4-bromomethyl-5-tert-butyl-2-oxo-1,3-dioxolene；4-(bromomethyl)-5-tert-butyl-1,3-dioxol-2-one；4-bromomethyl-5-tert-butyl-2-oxo-1,3-dioxole；5-tert-butyl-4-bromomethyl-1,3-dioxol-2-one；4-Bromomethyl-5-(1.1-dimethylethyl)-1.3-dioxacyclopenten-2-one；tert-butyl-2-oxo-1,3-dioxolen-4-yl-methelenyl bromide
• CAS: 86005-12-1
• 化学式: C₈H₁₁BrO₃
• 分子量: 235.078
• InChiKey: VLAJSDGHBCCRAX-UHFFFAOYSA-N

物化性质

• 沸点：
  224.6±42.0 °C(Predicted)
• 密度：
  1.496±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(bromomethyl)-5-(tert-butyl)-1,3-dioxol-2-one 在 盐酸 、 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 (5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl (2S)-2-[(3S)-3-aminopyrrolidin-1-yl]-3-(4,5-dihydroimidazo[1,5-a]quinolin-3-yl)propanoate trihydrochloride
  参考文献：
  名称：

  [EN] COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
  [FR] COMPOSES AYANT UNE ACTIVITE INHIBITRICE DU TAFIA

  摘要：

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：(I)其中R是氢原子或C1-10烷基基团；R1是氢原子、C1-10烷基基团、C3-8环烷基基团或具有以下式Ia或Ib所代表的结构的取代基：(Ia) (Ib)其中R3是C1-6烷基基团；R4是C1-6烷基基团、C3-8环烷基基团或苄基；R2是氢原子或具有以下式Ic或Id所代表的结构的取代基：(Ic) (Id)

  公开号：

  WO2011034215A1
• 作为产物：
  描述：

  特戊酰基乙酸乙酯 在 dirhodium tetraacetate 、 palladium hydroxide - carbon 4-二甲氨基吡啶 、 对甲苯磺酰叠氮 、 草酰氯 、 四溴化碳 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， -78.0~20.0 ℃ 、101.33 kPa 条件下， 生成 4-(bromomethyl)-5-(tert-butyl)-1,3-dioxol-2-one
  参考文献：
  名称：

  A general synthesis of dioxolenone prodrug moieties

  摘要：

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)02386-3

文献信息

• Prodrugs of imidazole carboxylic acids as angiotensin II receptor
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US05310929A1

  公开（公告）日：1994-05-10

  Prodrugs of imidazole carboxylic acids which are AII antagonists useful in treating hypertension, pharmaceutical compositions thereof and a method of treating hypertension using such prodrugs are disclosed.

  咪唑羧酸的前药是AII拮抗剂，对治疗高血压有用，公开了这些前药的药物组合物以及使用这些前药治疗高血压的方法。
• [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005097760A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及替代前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药，包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法，以治疗和/或预防人类和动物中的HCV感染。
• Design, Synthesis, Structure–Function Relationship, Bioconversion, and Pharmacokinetic Evaluation of Ertapenem Prodrugs
  作者：Sheo B. Singh、Diane Rindgen、Prudence Bradley、Takao Suzuki、Nengxue Wang、Hao Wu、Basheng Zhang、Li Wang、Chongmin Ji、Hongshi Yu、Richard M. Soll、David B. Olsen、Peter T. Meinke、Deborah A. Nicoll-Griffith

  DOI：10.1021/jm500879a

  日期：2014.10.23

  Described here are synthesis and biological evaluations of diversified groups of over 57 ertapenem prodrugs which include alkyl, methylenedioxy, carbonate, cyclic carbonate, carbamate esters, and esters containing active transport groups (e.g., carboxyl, amino acid, fatty acids, cholesterol) and macrocyclic lactones linking the two carboxyl groups. Many of the prodrugs were rapidly hydrolyzed in rat

  这里描述的是超过57种厄他培南前药的多样化基团的合成和生物学评估，这些药物包括烷基，亚甲二氧基，碳酸酯，环状碳酸酯，氨基甲酸酯以及含有活性转运基团（例如羧基，氨基酸，脂肪酸，胆固醇）和大环酯的酯连接两个羧基的内酯。许多前药在大鼠血浆中迅速水解，但在人血浆中不迅速水解，并且在模拟胃肠道液中稳定。通过犬内注射给药，二乙酯前药显示出最佳的总吸收（> 30％），这可能会通过制剂开发而得到改善。然而，其缓慢水解为厄他培南的速率也导致大量循环单酯代谢物的存在，这构成了显着的开发挑战。
• Studies on prodrugs. II. Preparation and characterization of (5-substituted 2-Oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin.
  作者：FUMIO SAKAMOTO、SHOJI IKEDA、GORO TSUKAMOTO

  DOI：10.1248/cpb.32.2241

  日期：——

  (5-Substituted 2-oxo-1, 3-dioxolen-4-yl) methyl esters were designed as a new type of ampicillin prodrug. These esters were prepared and confirmed to produce higher blood levels of ampicillin than ampicillin trihydrate itself after oral administration to mice. The compounds which produced particularly high blood levels of ampicillin were found to be hydrolyzed readily in blood in vitro. Ampicillin (5-methyl-2-oxo-1, 3-dioxolen-4-yl) methyl ester hydrochloride (KBT-1585) showed the best oral absorbability in mice.

  (5-取代的2-氧基-1,3-二恶烷-4-基)甲酸酯被设计为一种新型的青霉素前药。这些酯类化合物的制备经过确认，在小鼠口服给药后能产生比青霉素三水合物本身更高的血药浓度。那些能显著提高青霉素血药浓度的化合物在体外血液中容易水解。青霉素（5-甲基-2-氧基-1,3-二恶烷-4-基）甲酸酯盐酸盐（KBT-1585）在小鼠中显示出最佳的口服吸收性。
• Studies on prodrugs. IV. Preparation and characterization of N-(5-substituted 2-oxo-1,3-dioxol-4-yl)methyl norfloxacin.
  作者：FUMIO SAKAMOTO、SHOJI IKEDA、HIROSATO KONDO、GORO TSUKAMOTO

  DOI：10.1248/cpb.33.4870

  日期：——

  As a new type of norfloxacin (NFLX) prodrug, N-(5-substituted 2-oxo-1, 3-dioxol-4-yl) methyl NFLXs were designed. These N-masked NFLXs were prepared and confirmed to produce higher NFLX levels in blood than NFLX itself after oral administration to mice. N-(5-Methyl-2-oxo-1, 3-dioxol-4-yl) methyl NFLX was found to be smoothly hydrolyzed in mouse blood in vitro, and when administered orally, gave about 5-fold higher blood levels of NFLX than NFLX itself. Thus, the (5-methyl-2-oxo-1, 3-dioxol-4-yl) methyl group was confirmed to function as an amine-type promoiety.

  作为一种新型的诺氟沙星（NFLX）前药，设计了N-(5-取代的2-氧代-1,3-二噁烷-4-基)甲基NFLX。这些N掩蔽的NFLX被制备并确认在口服给药给小鼠后，其血液中的NFLX水平高于NFLX本身。研究发现，N-(5-甲基-2-氧代-1,3-二噁烷-4-基)甲基NFLX在小鼠血液中体外平稳水解，口服给药后，NFLX的血液水平约为NFLX本身的5倍。因此，(5-甲基-2-氧代-1,3-二噁烷-4-基)甲基基团被确认具有胺型促活基的功能。